Results 21 to 30 of about 212,694 (168)

Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy

open access: yesScientific Reports, 2021
Hypertrophic cardiomyopathy (HCM) is characterized by phenotypic heterogeneity. We investigated the molecular basis of the cardiac phenotype in two mouse models at established disease stage (mouse-HCM), and human myectomy tissue (human-HCM).
Styliani Vakrou   +11 more
doaj   +1 more source

Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundThe subcutaneous implantable cardioverter defibrillator (S‐ICD) has been developed to avert risks associated with transvenous defibrillator leads. The technology is attractive for younger patients, such as those with hypertrophic cardiomyopathy
Jonathan Weinstock   +4 more
doaj   +1 more source

Availability and Utilization of Automated External Defibrillators in New York State Schools

open access: yesFrontiers in Pediatrics, 2021
Background: Use of automated external defibrillators (AEDs) in out-of-hospital cardiac arrests (OHCAs) improve survival. Professional health organizations recommend that AEDs be available in crowded places, including schools but currently only 18 US ...
Milla Arabadjian   +3 more
doaj   +1 more source

Contemporary Insights Into the Genetics of Hypertrophic Cardiomyopathy: Toward a New Era in Clinical Testing?

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Genetic testing for hypertrophic cardiomyopathy (HCM) is an established clinical technique, supported by 30 years of research into its genetic etiology.
Francesco Mazzarotto   +6 more
doaj   +1 more source

Cardiomyocyte-targeted and 17β-estradiol-loaded acoustic nanoprobes as a theranostic platform for cardiac hypertrophy

open access: yesJournal of Nanobiotechnology, 2018
Background Theranostic perfluorocarbon nanoprobes have recently attracted attention due to their fascinating versatility in integrating diagnostics and therapeutics into a single system.
Xueli Zhao   +11 more
doaj   +1 more source

Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Our objective was to assess real‐world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy.
Ingy Mahana   +7 more
doaj   +1 more source

Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5 Years

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Disopyramide is used to treat heart failure symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM) with known medium‐term efficacy and safety, while long‐term outcomes are unknown. Methods and Results A total of 92 consecutive
Daniele Massera   +9 more
doaj   +1 more source

Automated segmentation of left ventricular myocardium using cascading convolutional neural networks based on echocardiography

open access: yesAIP Advances, 2021
Quickly and accurately segmenting the left ventricular (LV) myocardium from ultrasound images and measuring the thickness of the interventricular septum and LV wall play an important role in hypertrophic cardiomyopathy.
Shenghan Ren   +5 more
doaj   +1 more source

Prevalence of anxiety and depression symptoms in a sample of outpatients with ATTR cardiac amyloidosis

open access: yesFrontiers in Psychology, 2023
Patients with ATTR cardiac amyloidosis (ATTR-CA) face rare disease that could negatively influence psychological well-being with consequences on the course of the disease and quality of life.
Martina Smorti   +16 more
doaj   +1 more source

Cardiomyopathy and phaeochromocytoma [PDF]

open access: yesAnaesthesia, 1983
Summary A ease is presented of phaeochromocytoma with catecholamine‐induced cardiomyopathy. The difficulties in the management when left ventricular failure occurred are reported and the importance of monitoring pulmonary artery pressure during the anaesthetic procedure is stressed.
F J, Gilsanz   +4 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy